CARB-X Funds Module Innovations
Rapid easy-to-use diagnostic would indicate which antibiotics would be effective against the bacterial pathogen causing the UTI.
Carb-X Funds Microbion
Company will develop inhaled drug to treat cystic fibrosis-related lung infections.
May 28, 2020 CARB-X.orgCarb-X Awards Day Zero Diagnostics $6.2m to Develop a New Test to Diagnose Deadly Superbug Infections Faster and Determine What Antibiotic Would Be Most Effective
Day Zero’s diagnostic is the 60th project funded by CARB-X since 2016.
May 12, 2020 Carb-x.orgAntibiotic Pipeline in Peril from Coronavirus and Incentives System
Kevin Outterson quoted in Axios.
Coronavirus Lessons for the Fight against ‘Superbugs’
Kevin Outterson quoted in Financial Times.
CARB-X Funds Peptilogics
To develop a new class of antibiotics to treat serious superbug infections associated with implants.
New Genomic Tests Aim to Diagnose Deadly Infections Faster
Kevin Outterson quoted in The New York Times.
CARB-X Funds Lytica Therapeutics
The funding will help develop antibacterial peptides to treat drug-resistant infections in the lungs and other parts of the body.
Malvern Drugmaker Is Hopeful Where Others Struggle: Fighting Deadly ‘Superbugs’
CARB-X featured in The Philadelphia Inquirer.
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
Kevin Outterson quoted in BussinessWire.